Clinical Trial Update: Safety and Immunogenicity of Novartis Meningococcal ACWY Conjugate Vaccine in Healthy Children Aged 12-59 Months. [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial evaluating the safety and immunogenicity of the Novartis Meningococcal ACWY Conjugate Vaccine in healthy children aged 12–59 months has…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Meningococcal Meningitis

Drugs mentioned

• Novartis Meningococcal ACWY Conjugate Vaccine (Meningococcal ACWY conjugate vaccine)

Snippet

Sponsor: Novartis Vaccines | Conditions: Meningococcal Meningitis | Phase 2 | Status: COMPLETED | Results posted: 2015-11-06